Racial/Ethnic Disparities in Medical Advantage Plan Enrollees

Share this content:
Racial/Ethnic Disparities in Medical Advantage Plan Enrollees
Racial/Ethnic Disparities in Medical Advantage Plan Enrollees

WEDNESDAY, Dec. 10, 2014 (HealthDay News) -- Racial and ethnic disparities exist among Medicare Advantage Plan enrollees, and improved performance on quality measures is accompanied by increased racial/ethnic equity, according to two studies published in the Dec. 11 issue of the New England Journal of Medicine.

John Z. Ayanian, M.D., M.P.P., from the University of Michigan Medical School in Ann Arbor, and colleagues compared the age- and sex-adjusted proportions of elderly enrollees in Medicare Advantage health plans with adequate control of blood pressure, cholesterol, and glycated hemoglobin. The researchers found that in 2006 and 2011, black enrollees were less likely to have adequate control of blood pressure, cholesterol, and glycated hemoglobin than white enrollees (P < 0.001); in 2011, Hispanic enrollees were also less likely to have adequate control (P ≤ 0.02 for all comparisons).

Amal N. Trivedi, M.D., M.P.H., from the Providence Veterans Affairs Medical Center in Rhode Island, and colleagues assessed performance rates for quality measures covering acute myocardial infarction, heart failure, and pneumonia among non-Hispanic white, non-Hispanic black, and Hispanic patients. The researchers found that between 2005 and 2010 there was a 3.4 percent improvement in adjusted performance rates for the 17 quality measures (P < 0.001 for all comparisons). In 2005, adjusted performance rates were more than 5 percent lower for black and Hispanic patients on three and six measures, respectively, compared with white patients; these gaps decreased significantly between 2005 and 2010.

"Our study provides support for the notion that efforts to improve the overall quality of care may also reduce racial and ethnic disparities," Trivedi and colleagues write.

Full Text - Ayanian (subscription or payment may be required)
Full Text - Trivedi (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths